A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Interferon beta-1a (IFNbeta-1a) is a treatment for relapsing multiple sclerosis (MS).
• The optimal dosage of IFNbeta-1a for MS treatment remains undetermined.
• This study addresses the need to establish the most effective dose for managing MS.

Purpose of the Study:

• To compare the efficacy of two intramuscular doses of IFNbeta-1a (30 mcg vs. 60 mcg weekly) in treating relapsing MS.
• To assess the impact of different IFNbeta-1a doses on disability progression.
• To evaluate secondary endpoints including relapses, MRI outcomes, and safety profiles.

Main Methods:

• A double-blind, parallel-group, dose-comparison study involving 802 patients with relapsing MS.
• Randomization to either 30 mcg or 60 mcg of intramuscular IFNbeta-1a administered weekly for at least 36 months.
• Primary endpoint: time to sustained disability progression (>=1.0 point increase on EDSS for 6 months).

Main Results:

• No significant difference in disability progression rates between the 30 mcg and 60 mcg IFNbeta-1a groups (HR 0.96, p=0.73).
• Kaplan-Meier estimates showed 37% disability progression in both groups by 36 months.
• No dose-dependent effects observed on secondary clinical endpoints; minor MRI differences noted at one time point. Higher incidence of flu-like symptoms and muscle weakness in the 60 mcg group.

Conclusions:

• Intramuscular interferon beta-1a at 30 mcg and 60 mcg weekly doses demonstrated comparable efficacy in clinical and MRI measures for relapsing MS.
• Both doses were generally well-tolerated, with slightly increased adverse events at the higher dose.
• The study suggests no added clinical benefit from the 60 mcg dose over the 30 mcg dose in this patient population.